drugset
drugset / Trial / NCT00791661

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

NCT00791661 ↗

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe and well tolerated, based on the assessment of clinical and laboratory evaluations and adverse experiences, in Japanese participants with T2DM.

Timeline

Start
2008-11
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1006 Unknown 15 mg Oral
Subject MK-1006 Unknown 30 mg Oral
Subject MK-1006 Unknown 45 mg Oral
Subject MK-1006 Unknown 60 mg Oral
Subject MK-1006 Unknown 80 mg Oral
Subject MK-1006 Unknown 100 mg Oral
Subject MK-1006 Unknown 140 mg Oral
Subject MK-1006 Unknown 170 mg Oral

Indications

type 2 diabetes mellitus